<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01434121</url>
  </required_header>
  <id_info>
    <org_study_id>HM12903</org_study_id>
    <nct_id>NCT01434121</nct_id>
  </id_info>
  <brief_title>Ascorbic Acid (Vitamin C) Infusion in Human Sepsis</brief_title>
  <official_title>Ascorbic Acid (Vitamin C) Infusion in Human Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The major goal of this project is to determine whether intravenously infused ascorbic acid is
      safe for use as a viable therapeutic strategy in adult humans with sepsis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evolving data from experimental animals strongly suggests that ascorbic acid potently
      interrupts multiple biological processes which lead to organ injury following onset of
      sepsis. Data presented below suggests that ascorbic acid potently attenuates lung injury
      produced by septic insults. Sepsis and septic shock secondary to bacterial and fungal blood
      stream infections are a leading cause of death in critically ill patients. At present, 28 day
      mortality in septic patients averages 40% in the best of ICUs. In sepsis, disseminated
      intravascular coagulation produces widespread systemic microvascular thrombosis that leads to
      multiple organ injury (i.e., lung, liver, kidney, intestinal, cardiovascular). Despite
      aggressive intravascular volume resuscitation and vasopressor support, appropriate antibiotic
      administration, and expert critical care management, mortality remains high. Only a single
      agent has been approved to disrupt progressive sepsis-associated microvascular thrombosis
      (activated protein C, [Drodrecogin Alpha, brand name: Xigris, Lilly]). No other
      non-antibiotic pharmaceutical agent is currently approved for use in sepsis. Activated
      protein C (APC) continuous infusion protocol spans a 96 hour period. APC infusion produces
      significant anticoagulation, and therefore the major risk from its use is hemorrhage. Thus,
      recent surgery, especially neurosurgical procedures, is a major contraindication to APC use.
      Finally, cost stands as an important issue for APC use. A 96 hour APC infusion in a 70 kg
      patient at VCUHS costs the patient over $33,000 (source VCUHS Pharmacy Services). Use of APC
      in sepsis remains controversial and has failed to achieve widespread acceptance. The goal of
      the current study is to determine the safety of ascorbic acid infusion in septic humans.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Who Experienced Ascorbic Acid Infusion Related Arterial Hypotension, Vomiting, or Tachycardia in Septic Patients</measure>
    <time_frame>during time of infusion- 96 hours from time of enrollment</time_frame>
    <description>There were no instances of arterial hypotension, vomiting, or tachycardia within the study population related to the study drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intensive Care Unit Length of Stay</measure>
    <time_frame>subject will be followed until discharged from the ICU, has deceased, or study duration has reached 28 days from time of enrollment, whichever is first</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Mechanical Ventilation</measure>
    <time_frame>subject will be followed until mechanical ventilation has been discontinued, the subject has deceased, or study duration has reached 28 days from time of enrollment, whichever is first</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free Days</measure>
    <time_frame>subject will be followed until discharged from the hospital, has deceased, or study duration has reached 28 days from time of enrollment, whichever is first</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Time on Vasopressor Medication</measure>
    <time_frame>during time of infusion - 96 hours from time of enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Organ Dysfunction Score</measure>
    <time_frame>during time of infusion - 96 hours from time of enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Cytokine/Chemokine Levels</measure>
    <time_frame>during time of infusions - 96 hours from time of enrollment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Sepsis</condition>
  <condition>Septic Shock</condition>
  <condition>Hypotension</condition>
  <condition>Acute Lung Injury</condition>
  <arm_group>
    <arm_group_label>High Dose Ascorbic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject receives a high dose of infused Vitamin C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Ascorbic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject receives a low dose of infused Vitamin C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subject receives an infusion of saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbic Acid</intervention_name>
    <description>The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo</description>
    <arm_group_label>High Dose Ascorbic Acid</arm_group_label>
    <arm_group_label>Low Dose Ascorbic Acid</arm_group_label>
    <other_name>Vitamin C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. systemic inflammatory response: fever (38°C or greater) or hypothermia (36°C or
             lower), tachypnea (20 breaths/min) or need for mechanical ventilation for an acute
             process, tachycardia (rate 90/min or more), white blood cell count ≥ 12,000 cells/mm3
             or ≤ 4,000 cells/mm3 or more than 10% band forms.

          2. Presumed or Known Site of Infection: Purulent sputum, chest radiograph with new
             infiltrate, spillage of bowel contents, radiographic or physical examination evidence
             of an infected collection, white blood cells in a normally sterile body fluid,
             positive blood culture, evidence of infected mechanical hardware by physical,
             radiographic, or ultrasonographic evidence.

          3. Evidence of Dysfunction of One or More End Organs: cardiovascular dysfunction: mean
             arterial pressure 60 mm Hg or less, the need for vasopressors to maintain this
             pressure in the presence of adequate intravascular volume (central venous pressure 12
             mmHg); respiratory failure: (arterial PO2-to-FiO2 ratio of less than 250 or less than
             200 in the presence of pneumonia; renal dysfunction: Urine output ≤ 0.5 ml/kg/hr for 2
             hours in the presence of adequate intravascular volume or doubling of the serum
             creatinine; hematologic dysfunction: thrombocytopenia ≤ 80,000 platelets/mm3 or 50%
             decrease from baseline during the acute illness; Unexplained metabolic acidosis:
             arterial pH ≤ 7.3 and a plasma lactate level higher than 2.5. Hepatic Dysfunction:
             Acute Serum transaminase elevation greater than five times normal.

          4. Informed Consent: Ability to obtain informed consent within 48 hours.

        Exclusion Criteria:

          1. Demographic Characteristics: Children (age &lt; 18 years), pregnant women, prisoners, and
             other wards of the state are excluded from participation in this study.

          2. Informed Consent: Inability to obtain informed consent within 48 hours.

          3. Cognitive Impairment: In the absence of family or next of kin, if the investigators
             feel the patient is cognitively impaired, and unable to provide informed consent, the
             patient will not be accessed to the study.

          4. Non-English Speaking Patients: Patients who are non english speaking will not be
             accessed to this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alpha Fowler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2011</study_first_submitted>
  <study_first_submitted_qc>September 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2011</study_first_posted>
  <results_first_submitted>March 4, 2014</results_first_submitted>
  <results_first_submitted_qc>May 30, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 1, 2014</results_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Hypotension</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>High Dose Ascorbic Acid</title>
          <description>Subject receives a high dose of infused Vitamin C
Ascorbic Acid vs. Placebo: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo</description>
        </group>
        <group group_id="P2">
          <title>Low Dose Ascorbic Acid</title>
          <description>Subject receives a low dose of infused Vitamin C
Ascorbic Acid vs. Placebo: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Subject receives an infusion of saline
Ascorbic Acid vs. Placebo: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High Dose Ascorbic Acid</title>
          <description>Subject receives a high dose of infused Vitamin C
Ascorbic Acid vs. Placebo: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo</description>
        </group>
        <group group_id="B2">
          <title>Low Dose Ascorbic Acid</title>
          <description>Subject receives a low dose of infused Vitamin C
Ascorbic Acid vs. Placebo: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Subject receives an infusion of saline
Ascorbic Acid vs. Placebo: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Who Experienced Ascorbic Acid Infusion Related Arterial Hypotension, Vomiting, or Tachycardia in Septic Patients</title>
        <description>There were no instances of arterial hypotension, vomiting, or tachycardia within the study population related to the study drug</description>
        <time_frame>during time of infusion- 96 hours from time of enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Ascorbic Acid</title>
            <description>Subject receives a high dose of infused Vitamin C
Ascorbic Acid vs. Placebo: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Ascorbic Acid</title>
            <description>Subject receives a low dose of infused Vitamin C
Ascorbic Acid vs. Placebo: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subject receives an infusion of saline
Ascorbic Acid vs. Placebo: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Experienced Ascorbic Acid Infusion Related Arterial Hypotension, Vomiting, or Tachycardia in Septic Patients</title>
          <description>There were no instances of arterial hypotension, vomiting, or tachycardia within the study population related to the study drug</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensive Care Unit Length of Stay</title>
        <time_frame>subject will be followed until discharged from the ICU, has deceased, or study duration has reached 28 days from time of enrollment, whichever is first</time_frame>
        <population>Limited data were collected for this assessment due to study termination. These data are no longer available and the study team does not have IRB approval to retroactively analyze the results</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Ascorbic Acid</title>
            <description>Subject receives a high dose of infused Vitamin C
Ascorbic Acid: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Ascorbic Acid</title>
            <description>Subject receives a low dose of infused Vitamin C
Ascorbic Acid: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subject receives an infusion of saline
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Intensive Care Unit Length of Stay</title>
          <population>Limited data were collected for this assessment due to study termination. These data are no longer available and the study team does not have IRB approval to retroactively analyze the results</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Mechanical Ventilation</title>
        <time_frame>subject will be followed until mechanical ventilation has been discontinued, the subject has deceased, or study duration has reached 28 days from time of enrollment, whichever is first</time_frame>
        <population>Limited data were collected for this assessment due to study termination. These data are no longer available and the study team does not have IRB approval to retroactively analyze the results</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Ascorbic Acid</title>
            <description>Subject receives a high dose of infused Vitamin C
Ascorbic Acid vs. Placebo: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Ascorbic Acid</title>
            <description>Subject receives a low dose of infused Vitamin C
Ascorbic Acid vs. Placebo: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subject receives an infusion of saline
Ascorbic Acid vs. Placebo: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Mechanical Ventilation</title>
          <population>Limited data were collected for this assessment due to study termination. These data are no longer available and the study team does not have IRB approval to retroactively analyze the results</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventilator-free Days</title>
        <time_frame>subject will be followed until discharged from the hospital, has deceased, or study duration has reached 28 days from time of enrollment, whichever is first</time_frame>
        <population>Limited data were collected for this assessment due to study termination. These data are no longer available and the study team does not have IRB approval to retroactively analyze the results</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Ascorbic Acid</title>
            <description>Subject receives a high dose of infused Vitamin C
Ascorbic Acid vs. Placebo: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Ascorbic Acid</title>
            <description>Subject receives a low dose of infused Vitamin C
Ascorbic Acid vs. Placebo: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subject receives an infusion of saline
Ascorbic Acid vs. Placebo: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Ventilator-free Days</title>
          <population>Limited data were collected for this assessment due to study termination. These data are no longer available and the study team does not have IRB approval to retroactively analyze the results</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Time on Vasopressor Medication</title>
        <time_frame>during time of infusion - 96 hours from time of enrollment</time_frame>
        <population>Limited data were collected for this assessment due to study termination. These data are no longer available and the study team does not have IRB approval to retroactively analyze the results</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Ascorbic Acid</title>
            <description>Subject receives a high dose of infused Vitamin C
Ascorbic Acid vs. Placebo: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Ascorbic Acid</title>
            <description>Subject receives a low dose of infused Vitamin C
Ascorbic Acid vs. Placebo: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subject receives an infusion of saline
Ascorbic Acid vs. Placebo: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Time on Vasopressor Medication</title>
          <population>Limited data were collected for this assessment due to study termination. These data are no longer available and the study team does not have IRB approval to retroactively analyze the results</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multiple Organ Dysfunction Score</title>
        <time_frame>during time of infusion - 96 hours from time of enrollment</time_frame>
        <population>Limited data were collected for this assessment due to study termination. These data are no longer available and the study team does not have IRB approval to retroactively analyze the results</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Ascorbic Acid</title>
            <description>Subject receives a high dose of infused Vitamin C
Ascorbic Acid vs. Placebo: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Ascorbic Acid</title>
            <description>Subject receives a low dose of infused Vitamin C
Ascorbic Acid vs. Placebo: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subject receives an infusion of saline
Ascorbic Acid vs. Placebo: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Organ Dysfunction Score</title>
          <population>Limited data were collected for this assessment due to study termination. These data are no longer available and the study team does not have IRB approval to retroactively analyze the results</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Cytokine/Chemokine Levels</title>
        <time_frame>during time of infusions - 96 hours from time of enrollment</time_frame>
        <population>Limited data were collected for this assessment due to study termination. These data are no longer available and the study team does not have IRB approval to retroactively analyze the results</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Ascorbic Acid</title>
            <description>Subject receives a high dose of infused Vitamin C
Ascorbic Acid vs. Placebo: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Ascorbic Acid</title>
            <description>Subject receives a low dose of infused Vitamin C
Ascorbic Acid vs. Placebo: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subject receives an infusion of saline
Ascorbic Acid vs. Placebo: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Cytokine/Chemokine Levels</title>
          <population>Limited data were collected for this assessment due to study termination. These data are no longer available and the study team does not have IRB approval to retroactively analyze the results</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>96 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>High Dose Ascorbic Acid</title>
          <description>Subject receives a high dose of infused Vitamin C
Ascorbic Acid vs. Placebo: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo</description>
        </group>
        <group group_id="E2">
          <title>Low Dose Ascorbic Acid</title>
          <description>Subject receives a low dose of infused Vitamin C
Ascorbic Acid vs. Placebo: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Subject receives an infusion of saline
Ascorbic Acid vs. Placebo: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alpha A. Fowler, III, MD</name_or_title>
      <organization>Virginia Commonweath University</organization>
      <phone>804-628-5710</phone>
      <email>afowler@mcvh-vcu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

